News

The double-blind, placebo-controlled phase 2 study included 125 patients over the age of 18 and was undertaken across nearly 25 clinical sites in the US. Patients were randomized

The planned start of the Phase 1b/2 study (68284528MMY2001), scheduled to begin enrollment in the second half of 2018, follows the US Food and Drug Administration (FDA) clearance

The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations. This news follows the announcement earlier this month that the first pivotal Phase III

The approval is for the drug to be taken orally twice daily (BID) in 10mg dosage for at least eight weeks, followed by 5mg BID or 10mg BID

Larotrectinib is an oral and highly selective investigational tropomyosin receptor kinase (TRK) inhibitor, which is currently under clinical development to treat patients with cancers that harbor a NTRK

Rubraca has been authorized as a monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary

MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization. Ipsen research & development executive vice

The late-stage trial, dubbed IMpower130, assessed the efficacy and safety of Tecentriq in combination with carboplatin and nab-paclitaxel versus chemotherapy (carboplatin and nab-paclitaxel) alone for chemotherapy-naïve patients with stage IV non-squamous

OliX CEO Dong-ki Lee said:  "The approval of this CTA marks an important milestone for OliX's RNAi therapeutic development, by demonstrating that OliX has met and qualified against the